A patient-derived xenograft (PDX) model demonstrating dose-dependent tumor growth inhibition with enzalutamide treatment in prostate cancer.

Patentradars sammanfattning

This document presents preclinical efficacy data for enzalutamide, an androgen receptor antagonist, tested across multiple dose levels (10-80 mg/kg) in a Lucap 73 patient-derived xenograft (PDX) model. The study tracks tumor volume progression over 42 days post-treatment, establishing dose-response relationships critical for clinical translation. The PDX model represents a physiologically relevant preclinical platform for evaluating advanced prostate cancer therapeutics.

AI-genererad och redaktionellt processad.